Internal Medicine, Endocrinology, Diabetes, & Metabolism · Meadville, PA
NPI
1629455340
Since 2015
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
765 Liberty St Ste 307-A
Meadville, PA, 16335
Phone (814) 373-4270
Groups this clinician bills Medicare through
Medicare paid, 2024
$64K
1,078 services
Medicare patients, 2024
367
Average age 71
Drug cost, 2024
$4.1M
6,841 prescriptions
Company payments, 2025
$907
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gagandeep S Grewal was code 99214 (office e&m - established), 683 times for 289 patients. In total Gagandeep S Grewal billed 1,078 services in 12 codes, and Medicare paid $64K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-08-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 683 | 289 | $67.34 | $46K |
| 95251 Test - Miscellaneous | Office | 239 | 87 | $25.72 | $6,147 |
| 99204 Office E&M - New | Office | 75 | 75 | $97.59 | $7,319 |
| 99213 Office E&M - Established | Office | 40 | 31 | $43.97 | $1,759 |
| 99203 Office E&M - New | Office | 14 | 14 | $63.96 | $895 |
By year: 2022 $73K for 885 services; 2023 $73K for 987 services; 2024 $64K for 1,078 services.
Medicare prescription drug claims, 2024
In 2024, the drug Gagandeep S Grewal prescribed most often to Medicare patients was Ozempic (Semaglutide), with 651 prescriptions and refills. In total Gagandeep S Grewal wrote 6,841 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 651 | 1,030 | 134 | $973K |
| Mounjaro Tirzepatide | 648 | 901 | 122 | $932K |
| Metformin Hcl Er Metformin Hcl | 582 | 1,415 | 173 | $13K |
| Jardiance Empagliflozin | 509 | 1,102 | 130 | $627K |
| Levothyroxine Sodium Generic | 466 | 1,051 | 116 | $4,658 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 335 | 896 | 125 | $51K |
| Metformin Hcl Generic | 323 | 703 | 79 | $3,031 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 191 | 544 | 89 | $22K |
| Pioglitazone Hcl Generic | 165 | 435 | 50 | $2,908 |
| Trulicity Dulaglutide | 148 | 228 | 49 | $220K |
| Glipizide Er Glipizide | 137 | 327 | 50 | $2,387 |
| Humalog Kwikpen U-100 Insulin Lispro | 111 | 240 | 49 | $41K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 109 | 308 | 40 | $52K |
| Rosuvastatin Calcium Generic | 103 | 266 | 31 | $1,685 |
| Novolog Flexpen Insulin Aspart | 95 | 201 | 41 | $31K |
Brand drugs: 3,751 claims; generic drugs: 2,712 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gagandeep S Grewal $907 ($907 in general payments such as food, travel and fees) from 17 companies. The largest payer was Novo Nordisk Inc with $217.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 16 | $217 |
| Tandem Diabetes Care, Inc. TNDM | 13 | $125 |
| Lilly USA, LLC LLY | 4 | $82.12 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $60.5 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $55.53 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $52.79 |
| Corcept Therapeutics CORT | 3 | $46.65 |
| Amneal Pharmaceuticals LLC AMRX | 2 | $38.65 |
| Ascendis Pharma Endocrinology Inc ASND | 2 | $38.58 |
| Amgen Inc. AMGN | 2 | $38.11 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.